DUBLIN–(BUSINESS WIRE)–The “2022 United States Vaccine Market Report” report has been added to ResearchAndMarkets.com’s offering.
The U.S. vaccine market is expected to reach $30 billion by 2027, fueled by COVID-19 vaccines, development of new vaccine technologies, and advances in clinical research.
The growth and approval of pediatric vaccinations and universal vaccine trials have also significantly contributed to the market expansion. The 2022 Vaccine Market Report describes the overall vaccine market, including the approval process, the impact of the COVID-19 pandemic, necessary vaccine supplies and market value for childhood, adult, influenza, and COVID-19 vaccines.
Key Findings
11.3 billion doses of COVID-19 vaccines were administered globally.
An estimated 11.1 million adult and adolescent vaccines were missed in 2021.
Pharmacies administered 14.9% less flu vaccines in 2022 compared to 2021.
In 2021, Pfizer sold $36 billion in vaccines breaking the 2015 record of $6.2 billion.
Key Topics Covered:
Executive Summary
Vaccine Market Overview
Vaccines Become Major Contributor To Pharmacy Revenue
Pharmacy Technicians Nationwide Now Authorized To Vaccinate
Insurance Or Government Programs Cover Most Recommended Vaccines
Influenza Vaccine Market Expected To Rebound From Pandemic Dip
More Adults Receive Flu Vaccinations At Pharmacies Than Doctors’ Offices
Pandemic Continues To Suppress Flu Vaccination, Including In High-Risk Groups
Universal Flu Vaccine Candidate Could Negate Annual Shots
First Cell-Based Flu Vaccine Offers Better Match To Circulating Strains
COVID-19 Vaccine Market Remains Strong
First COVID-19 Vaccines Approved, More In Development
2021 COVID-19 mRNA Success Fuels Nucleic Acid Vaccines For Other Diseases
COVID-19 Vaccines Increase In Price
COVID-19 Vaccine Setting Shifts Away From Nontraditional Megasites
Workplace Vaccine Mandates Remain Controversial
CDC Research Points To Need For Four Or More COVID-19 Doses.
COVID-19 Vaccine Split Widens On Rural Vs. Urban And Narrows On Race
Prefilled Syringes May Be On The Way For COVID-19 Vaccines
COVID-19 Vaccine Authorized For Children Under Five
U.S. Pediatric Vaccine Market Projected To Reach $6.64 Billion By 2027
First Six-In-One Combination Childhood Vaccine Hits The Market
Dengue And COVID-19 Vaccines Now Recommended For Some Children
HPV Vaccine Hesitancy Remains High
2-Dose HPV Vaccination Completion Tied To Wellness Visit Volume
CDC Makes Several Updates To Adult Immunization Schedule
Expanded Shingles Vaccine Recommendation May Be Coming
Appendices
For more information about this report visit https://www.researchandmarkets.com/r/p5htpy
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
